TY - PAT
T1 - Compositions and methods for preparing cd34neg stem cells for transplant
AU - Merzaban, Jasmeen S.
AU - Abu Samra, Dina Bashir Kamil
AU - Al-Amoodi, Asma
N1 - KAUST Repository Item: Exported on 2019-02-13
PY - 2018/9/27
Y1 - 2018/9/27
N2 - It has been discovered that CD34 neg cells, for example HSPCs, can be modified to increase their ability to migrate and to engraft in bone marrow. One embodiment provides a method for modifying CD34 neg cells by using glycosyltransferase-programmed stereosubstitution (GPS) to create relevant selectin-binding glycan determinants on the cell surface. For example, the CD34 neg cells can be treated with a fucosyltransferase, such as an α(1,3)-linkage-specific fucosyltransferase. Representative enzymes that can be used include, but are not limited to fucosyltransferase VI (FTVI or FucT-6) or fucosyltransferase VII (FTVII of FucT-7). These enzymes specifically places a fucose onto a terminal type 2-lactosamine unit; if that lactosamine is capped with an α(2,3)-linked sialic acid, sLe x is created.
AB - It has been discovered that CD34 neg cells, for example HSPCs, can be modified to increase their ability to migrate and to engraft in bone marrow. One embodiment provides a method for modifying CD34 neg cells by using glycosyltransferase-programmed stereosubstitution (GPS) to create relevant selectin-binding glycan determinants on the cell surface. For example, the CD34 neg cells can be treated with a fucosyltransferase, such as an α(1,3)-linkage-specific fucosyltransferase. Representative enzymes that can be used include, but are not limited to fucosyltransferase VI (FTVI or FucT-6) or fucosyltransferase VII (FTVII of FucT-7). These enzymes specifically places a fucose onto a terminal type 2-lactosamine unit; if that lactosamine is capped with an α(2,3)-linked sialic acid, sLe x is created.
UR - http://hdl.handle.net/10754/629849
UR - https://patents.google.com/patent/WO2018172869A1/en
M3 - Patent
M1 - WO2018172869A1
ER -